
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2026 EPS estimates for Beam Therapeutics in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($4.35) per share for the year, down from their prior estimate of ($4.33). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share.
BEAM has been the subject of several other reports. Bank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 price objective for the company in a report on Friday, March 28th. Guggenheim cut their price objective on Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company cut their price objective on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Beam Therapeutics in a report on Monday, April 7th. Finally, Barclays lowered their target price on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $48.75.
View Our Latest Stock Analysis on Beam Therapeutics
Beam Therapeutics Stock Performance
Shares of NASDAQ:BEAM traded down $1.21 during midday trading on Monday, hitting $20.95. 2,879,018 shares of the stock were exchanged, compared to its average volume of 2,421,002. Beam Therapeutics has a 52-week low of $13.52 and a 52-week high of $35.25. The business's fifty day simple moving average is $18.33 and its two-hundred day simple moving average is $21.44. The company has a market capitalization of $2.11 billion, a PE ratio of -4.54 and a beta of 2.07.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative return on equity of 44.24% and a negative net margin of 609.24%. The firm had revenue of $7.47 million for the quarter, compared to analysts' expectations of $14.69 million. During the same quarter in the prior year, the business posted ($1.21) earnings per share. Beam Therapeutics's revenue was up 1.4% on a year-over-year basis.
Institutional Investors Weigh In On Beam Therapeutics
A number of hedge funds have recently bought and sold shares of BEAM. ARK Investment Management LLC boosted its holdings in Beam Therapeutics by 20.0% during the first quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company's stock valued at $165,616,000 after acquiring an additional 1,412,060 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Beam Therapeutics by 72.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,026,701 shares of the company's stock valued at $59,112,000 after acquiring an additional 1,273,559 shares during the period. Vanguard Group Inc. boosted its holdings in Beam Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock valued at $173,256,000 after acquiring an additional 1,249,303 shares during the period. EcoR1 Capital LLC bought a new stake in Beam Therapeutics during the first quarter valued at about $10,286,000. Finally, Woodline Partners LP boosted its holdings in Beam Therapeutics by 169.6% during the first quarter. Woodline Partners LP now owns 760,611 shares of the company's stock valued at $14,855,000 after acquiring an additional 478,491 shares during the period. 99.68% of the stock is currently owned by institutional investors.
About Beam Therapeutics
(
Get Free Report)
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Featured Articles

Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.